COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 5, 2025

The Coronavirus Disease 2019 (COVID-19) pandemic modified the organization of cancer care pathways worldwide. Few prospective long-term data assessing these therapeutic modifications are available. Clin-COVIDICA was a cohort aiming at determining clinical impact COVID-19-related in patients with digestive our center. All consecutive undergoing an oncologic treatment for from March 1 to April 30, 2020, were enrolled and followed-up 24 months. primary endpoint progression-free survival (PFS). Secondary endpoints included COVID-19 rate, adverse events (AE) overall (OS). Survival curves estimated using Kaplan-Meier method compared by log-rank test. Of 401 included, 39.6% female, mean age 68 years old most frequent tumor colorectal (50.0%) pancreatic (17.9%) cancers. all, 55 (13.7%) have undergone modifications. switch oral drug (capecitabine, 30.9%), holidays (29.1%) cancellation (18.2%). Considering palliative (n = 339), there non-significant trend longer OS (52.0 months versus 36.4 months, p 0.07) significant PFS (15.4 6.2 0.009) There more all grades AEs without (84.4% vs. 65.5%, < 0.001), but severe (grade 3-5) among (18.2% 8.7%, 0.048), especially drug, which resulted 8 one death. Six (1.5%) had COVID-19, death definitive curative surgery due consequences COVID-19. We observed no negative management. This may be selection less aggressive disease. More upon modifications, switching capecitabine. Clinicaltrials.gov: NCT04389684; date registration (15/05/2020).

Language: Английский

Differential reactivity of SARS‐CoV‐2 S‐protein T‐cell epitopes in vaccinated versus naturally infected individuals

Clinical & Translational Immunology, Journal Year: 2025, Volume and Issue: 14(5)

Published: May 1, 2025

Abstract Objectives Vaccine‐induced protective immunity against SARS‐CoV‐2 has proved difficult to sustain. Robust T‐cell responses are thought play an important role, but the spike protein (S‐protein), core vaccine antigen, following vaccination or natural infection incompletely understood. Methods Herein, reactivity of 170 putative S‐protein CD8 + and CD4 peptide epitopes in same individuals prior vaccination, after COVID‐19 again subsequent was assayed using a high‐throughput reverse transcription‐quantitative PCR (HTS‐RT‐qPCR) assay. Results The profile immunoreactive differed between infection. were localised primarily into two extra‐domanial regions. In contrast, recognised spread across antigen. Furthermore, naïve association with HLA‐A, while shifted epitope associations towards HLA‐B, particularly B7 supertype. Conclusion This study provides insight

Language: Английский

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination

npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)

Published: May 9, 2025

We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 patients, to discover clinical molecular determinants that predispose breakthrough infections. Patients B cell malignancies, differential expression of CD24, CDK14 PLEKHG1, were most susceptible infections, suggesting these may require more booster immunisations ameliorate cellular responses immune protection against COVID-19.

Language: Английский